Fig. 3
The incremental cost-effectiveness scatter plot of sacituzumab govitecan compared to chemotherapy in China. (Note: PD, progressive disease; PFS, progression-free survival; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year)